Monte Rosa Therapeutics has announced the pricing of a public offering to raise ~USD 100 million. The offer consists of the sale of 10,638,476 common shares for USD 4.70 per share and the subsequent offering of pre-funded warrants to purchase 10,638,524 shares for USD 4.69 per pre-funded warrant.
The offering is expected to close on or about May 20, 2024. The round was led by Dimension and a certain life-sciences-focused investor, with participation from new and existing investors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.